POST Online Media Lite Edition


NEWLY REPORTED COVID-19 CASES IN LAST 24 HOURS (6.22.2021, 12:50pm CEST, WHO):   India 53,256    Brazil 44,178    France 1,815    Turkey 5,091    Russia 17,378    The United Kingdom 9,072    Argentina 10,395    Columbia 27,818    Iran 10,485    Mexico 1,578    Peru 2,896    Indonesia 14,536    South Africa 13,155    Chile 5,205    Philippines 5,249    Iraq 5,235    Bangladesh 4,636    Japan 1,011    Malaysia 4,611    Nepal 1,584    United Arab Emirates 1,964    Saudi Arabia 1,212    Bolivia 1,086    Paraguay 1,145    Tunisia 2,478    Uruguay 1,488    Kuwait 1,935    Venezuela 1,327    Oman 2,529    Thailand 3,175    Cuba 1,561    Zambia 2,060    Afghanistan 1,847    Mongolia 2,268    Namibia 1,403    Uganda 1,367    China 103    Singapore 16    New Zealand 0    Australia 25    South Korea 395   

Non-steroidal anti-inflammatory drugs beyond 20 weeks of pregnancy, risk of kidney damage to unborn babies

Christian Fernsby |
Health Canada has completed a safety review confirming that the use of non-steroid anti-inflammatory drugs (NSAIDs) — such as acetylsalicylic acid (aspirin), ibuprofen, naproxen, diclofenac and celecoxib — starting from approximately 20 weeks of pregnancy or later, may cause rare but serious kidney problems in an unborn baby.

Article continues below

This can lead to low levels of amniotic fluid and possible complications, such as impaired lung maturation and loss of joint movement (limb contractures) in the newborn baby.

As a result of its findings, Health Canada is advising that pregnant women not use NSAIDs from approximately 20 to 28 weeks of pregnancy, unless advised to do so by their healthcare professional. Prescription and non-prescription NSAID product labels will be updated with this new information.

If a healthcare professional decides that the use of NSAIDs between 20 and 28 weeks of pregnancy is necessary, Health Canada recommends that they use the lowest effective dose for the shortest duration possible, and that they consider monitoring amniotic fluid levels via ultrasound if treatment extends beyond 48 hours. These recommendations do not apply to the use of low-dose (81 mg) aspirin, pediatric-only formulations (i.e., those only indicated for children less than 12 years of age) or NSAIDs administered directly to the eye.

Health Canada continues to monitor the situation closely and will take further action to help protect the health and safety of Canadians, if necessary. This includes continuing to work with Canadian manufacturers of NSAID products to take appropriate action in Canada in light of this new evidence.

What to read next

Good cholesterol may not always protect against heart disease
Scientists discover promising off-switch for inflammation
2.5 million U.S. women have condition that can cause infertility